Sunesis Pharmaceuticals

Sunesis Pharmaceuticals

Sunesis Pharmaceuticals was founded in 1995 and headquartered in South San Francisco, with additional offices across the US and in Zurich. The company was led by President and CEO Daniel Swisher and built a pipeline centered on kinase inhibitors and other small-molecule cancer treatments. Sunesis focused exclusively on oncology, with its most advanced asset being vosaroxin, a quinolone derivative that inhibits topoisomerase II. The compound reached a Phase III trial (VALOR) for relapsed/refractory AML but missed its primary endpoint in 2016. The firm also explored earlier-stage programs including SNS-595 and SNS-314, a pan-Aurora kinase inhibitor. Sunesis partnered with companies like Biogen Idec and Genentech on research collaborations. The firm funded its operations through public equity offerings, partnerships, and grant funding. At its peak Sunesis employed roughly 50–100 people and maintained a presence across North America and Europe. In August 2022, Viracta Therapeutics acquired Sunesis in an all-stock merger, folding its pipeline into Viracta's oncology portfolio. Sunesis was structurally distinct as a publicly traded biotechnology company rather than a family office or asset manager. Its model was venture-capital-backed drug development, not capital management. The firm's dissolution in 2022 marked the end of a 27-year run in oncology R&D.